Mozessohn, L. and Buckstein, R. (2020) “Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2025.288157.